Is Tamoxifen the Rosetta Stone for Breast Cancer?
- 5 March 2003
- journal article
- Published by Oxford University Press (OUP) in JNCI Journal of the National Cancer Institute
- Vol. 95 (5) , 338-340
- https://doi.org/10.1093/jnci/95.5.338
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- A role for TGF-β in estrogen and retinoid mediated regulation of the nuclear receptor coactivator AIB1 in MCF-7 breast cancer cellsOncogene, 2002
- Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trialThe Lancet, 2002
- Molecular Determinants for the Tissue Specificity of SERMsScience, 2002
- The Human Estrogen Receptor-α Is a Ubiquitinated Protein Whose Stability Is Affected Differentially by Agonists, Antagonists, and Selective Estrogen Receptor ModulatorsJournal of Biological Chemistry, 2001
- Ribozyme Targeting Demonstrates That the Nuclear Receptor Coactivator AIB1 Is a Rate-limiting Factor for Estrogen-dependent Growth of Human MCF-7 Breast Cancer CellsJournal of Biological Chemistry, 2001
- Cofactor competition between the ligand-bound oestrogen receptor and an intron 1 enhancer leads to oestrogen repression of ERBB2 expression in breast cancerOncogene, 2000
- Tamoxifen in the Treatment of Breast CancerNew England Journal of Medicine, 1998
- Designer EstrogensScientific American, 1998
- Tamoxifen for early breast cancer: an overview of the randomised trialsThe Lancet, 1998
- A NEW DERIVATIVE OF TRIPHENYLETHYLENE: EFFECT ON IMPLANTATION AND MODE OF ACTION IN RATSReproduction, 1967